Structure Therapeutics Inc. (GPCR) Earnings Call Transcripts

Structure Therapeutics Inc.'s Latest Earnings Call - June 9, 2026

Structure Therapeutics Inc. reported its Q2 2026 earnings, highlighting significant developments in its obesity treatment pipeline. The company emphasized the growth potential of the oral pill market, particularly for its GLP-1 and amylin combination therapies. Revenue and earnings specifics were not disclosed in the transcript, but the company maintained a strong cash position of $1.5 billion, sufficient to fund its Phase III weight management program through 2028. Management provided detailed insights into its Phase III trial design, which aligns with FDA guidelines, and discussed the strategic importance of its combination therapies in the evolving obesity market landscape.

Reported metrics

Guidance from management

Management maintained guidance for its Phase III trial, stating it will start in Q3 2026 and is expected to be completed with the current cash reserves by 2028. No changes to previous guidance were noted.

What management said

Yes. So this is a rapidly evolving space, as you can imagine, and price has been coming down. But the opportunity for us on small molecules is cost of goods are are really low, right, where cost of goods are going to be traditionally where small molecules are, and that gives us a real big advantage with respect to pricing. It's going to be different for oral peptides because their cost of goods are just going to be m...

Thing. It's really about you've modified your eating habits, smaller portions, your gastric emptying has sort of regulated even the sort of effects of food noise and everything have sort of settled down -- so this is the biological hypothesis being able to go over seamlessly to the same dose of oral but we need to do this experiment. So we're doing that right now. That will read out in Q4, and that will set the stage...

What analysts pressed on

Analysts expressed concerns about trial conduct challenges, particularly regarding patient discontinuations in placebo and treatment arms. There were also questions about the balance needed between GLP-1 and amylin in combination therapies.

Main topics on the call

• Oral Pill Market Growth — Management highlighted the rapid growth of the oral pill market, noting that '1% of the market is already oral pills' and '80% of it is growth.' This underscores the potential for oral treatments in the obesity sector.
• Phase III Trial Design — The company outlined its Phase III trial design, which includes a 52-week maintenance dose period and 4,500 participants. The trial is designed to meet FDA guidelines, focusing on long-term weight maintenance.
• Pricing Strategy — Structure Therapeutics emphasized its pricing advantage due to low cost of goods for small molecules, contrasting with higher costs for oral peptides.
• Phase II Efficacy Results — The company reported up to 16% weight loss in Phase II trials with no signs of plateauing, positioning its product as having a 'best-in-class profile in terms of efficacy.'

Read the full Structure Therapeutics Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 9 Structure Therapeutics Inc. earnings call transcripts on record, spanning June 3, 2024 to June 9, 2026. Based on this history, Structure Therapeutics Inc. reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

GPCR

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

9

First call

June 3, 2024

Most recent

June 9, 2026

Reporting cadence

quarterly